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ABSTRACT 
 
Background: There is a need for clinical tools to identify cultural issues in diagnostic assessment. 
Aims: Assess feasibility, acceptability, and clinical utility of the DSM-5 Cultural Formulation Interview 
(CFI) in routine clinical practice. 
Method: Mixed-methods evaluation of field trial data from six countries. The CFI was administered to 
diagnostically diverse psychiatric outpatients during a diagnostic interview. Post-evaluation session, 
patients and clinicians completed debriefing qualitative interviews and Likert-scale questionnaires. 
Durations of CFI administration and full diagnostic session were monitored.  
Results: Mixed-methods data from 318 patients and 75 clinicians found the CFI feasible, acceptable, and 
useful. Clinician feasibility ratings were significantly lower than patient ratings and other clinician-
assessed outcomes. After administering one CFI, however, clinician feasibility ratings improved 
significantly and subsequent interviews required less time.  
Conclusions: The CFI was included in DSM-5 as a feasible, acceptable, and useful cultural assessment 
tool. 
Declaration of interest: Three co-authors receive royalties from the CFI Handbook. 
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Unexamined cultural differences in how patients and clinicians frame illness and care may distort 
diagnosis and assessments of severity, impose communication barriers, compromise engagement, 
adherence, and response, and unnecessarily prolong patients’ suffering.1,2 Patient-clinician differences in 
age, gender, sexual orientation, socioeconomic status, race/ethnicity, religion, language, and/or national 
origin can contribute to cultural differences in all clinical interactions.3,4 The DSM-IV Outline for 
Cultural Formulation (OCF) is a conceptual framework that helps clinicians identify the impact of culture 
on illness and care during a clinical evaluation.5,6 The OCF is widely used in clinical training and cultural 
competence initiatives.7-10 However, its implementation in routine care has proved challenging:11 
clinicians had to improvise questions to collect the information, received limited guidance on which 
patients would benefit most, and faced uncertainty about whether to implement the OCF as a separate 
assessment or embed it in a standard clinical evaluation.12-14 The lack of a structured instrument also 
impeded research on cultural assessment and inclusion of cultural information in clinical trials.15,16  
In response, the American Psychiatric Association’s DSM-5 Cross-Cultural Issues Subgroup 
(DCCIS) developed the Cultural Formulation Interview (CFI)17 to operationalize the OCF for routine use 
in the clinical assessment of any patient, based on a literature review and consensus-building discussions 
with designers of OCF-based interviews.18 The CFI instruments comprise an initial assessment interview 
(core CFI), an informant interview for collateral information, and 12 supplementary modules that expand 
on these basic assessments. The core CFI consists of an introduction, open-ended questions for patients, 
and instructions to clinicians for each question. Acknowledging the need for global relevance and 
recognizing international work on the OCF, sites in six countries participated in the field trial. 
This report presents findings from the international field trial that tested the 14-item pilot version of 
the core CFI (Appendix 1) in three service domains based on patient and clinician feedback. Together 
with other field trial data not reported here, this process resulted in the final 16-item version in DSM-5.19 
We assessed several factors related to successful implementation of clinical innovations in service 
settings,20 including patient and clinician perceptions of the CFI’s feasibility (“Can it be done in clinical 
settings?”), acceptability (“Do patients and clinicians like it?”), and potential clinical utility (“Is it 
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helpful?”). We also considered whether closed- and open-ended assessments yielded similar results, and 
whether outcomes showed a practice effect, improving with experience. Our study is the first to examine 
these service domains for a tool to enhance cultural competence in multiple international settings.  
 
Methods 
Study design and settings 
The CFI field trial was designed by the DSM-5 DCCIS via regular teleconferences.19,21 The study 
was conducted from November 2011 to September 2012; the New York site coordinated logistics for all 
sites. The study design purposively included samples of diverse patients, clinician disciplines, and types 
of outpatient services, because a goal of the DSM-5 trials was to test the feasibility, acceptability, and 
utility of proposed diagnoses and assessments under varied clinical conditions to determine inclusion in 
DSM-5.22,23 Each site aimed to enrol at least 30 patients from affiliated psychiatric outpatient clinics in 
Canada (1 site), India (2), Kenya (1), the Netherlands (1), Peru (1), and the USA (5). Sites were chosen 
based on involvement of a principal investigator (PI) in the DCCIS and aimed to include diverse cultural 
populations and types of outpatient services (general community, immigrant/refugee, and ethnic-focus 
clinics). 
An opportunity sample of new and existing patients at each site was enrolled using a standard 
recruitment script. Clinicians who had no prior contact with their study patient conducted the interviews 
(“study clinicians”). Clinicians did not interview their own patients because prior knowledge and a pre-
existing relationship would confound study aims focusing on an initial assessment. Current patients were 
referred by treating clinicians to local study clinicians. Each study clinician was expected to interview 3-6 
patients during the trial to assess practice effects. Each patient participated only once. Patients and 
clinicians could also invite companions (e.g., relatives) to participate in the interview and subsequent 
assessments.24  
All study clinicians participated in a two-hour CFI training session at their site consisting of (1) 
reviewing the core CFI’s written guidelines; (2) a 24-minute video demonstration; (3) interactive 
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behavioural simulations with coaching and feedback from local PIs; and (4) a question-and-answer 
period.  
The study clinician administered the CFI followed by a routine diagnostic assessment. Topics of the 
CFI comprise four cultural domains: (i) definition of the problem; (ii) perceptions of cause, context, and 
support; (iii) factors affecting self-coping and past help-seeking; and (iv) factors affecting current help-
seeking.  
All sessions were audio-taped with patient consent. The study was approved by each site’s 
Institutional Review/Ethics Board and followed local informed consent regulations. All patients 
completed their locally-approved consent process. 
Participants 
Eligible patients were age 16 or older and fluent in the language of the local clinicians. We required 
the language match to avoid using interpreters who might introduce cultural information not obtained 
through the CFI. Patients were excluded if they were acutely suicidal or homicidal, intoxicated or in 
substance withdrawal, or if their condition seriously limited the assessment (e.g., dementia). Eligible 
study clinicians had a clinical degree permitting them to see patients, consistent with each country’s 
requirements.  
Assessments 
Pre-interview, patients and clinicians completed demographic surveys. Clinicians also indicated their 
professional training and cultural competence experiences. Local PIs identified demographic factors 
recognized by their governments as indicators of social differences, avoiding a USA-based 
characterization.19,25 After every session, study clinicians provided patients’ DSM-IV diagnoses and 
patients and clinicians completed follow-up questionnaires and semi-structured qualitative interviews. All 
assessments were translated into the local languages at each site and reviewed by a bilingual committee of 
mental health professionals for consensus.26  
Quantitative: Participants completed two brief questionnaires: the Debriefing Instrument for Patients 
(DIP) and the Debriefing Instrument for Clinicians (DIC), which comprise self-administered, Likert-scale 
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items assessing feasibility, acceptability, and clinical utility (Appendix 2) coded as “Strongly disagree,” 
“Disagree,” “Agree,” and “Strongly Agree.” As with other DSM-5 trials,22 these instruments were created 
for use in the CFI field trial. Items were selected for measurement by the DCCIS with reference to three 
domains (feasibility, acceptability, clinical utility) likely to affect the implementation of assessments like 
the CFI.20,22 The same content was included in each instrument, with wording adapted for each 
stakeholder group. As a measure of feasibility independent of self-report, we assessed the duration of the 
CFI and the total diagnostic interview (including the CFI), based on session audio files. 
Qualitative: Separate semi-structured qualitative interviews (8-9 questions, previously reported19:512) 
with patients and clinicians conducted by research assistants at each site provided more detailed accounts 
of the impact of the CFI on the initial evaluation. These interviews assessed participants’ perceptions of 
the most and least helpful aspects of the CFI, its impact on interview quality and outcomes, and its role in 
clinical practice, including diagnosis and treatment planning. Each site provided written English 
summaries of the interviews to the coordinating site. 
Analysis 
Quantitative: SAS version 9.4 (Cary, NC) was used for all analyses. 
Descriptive information: Patient and clinician characteristics were compared cross-nationally using 
ANOVA for continuous variables and Chi-square (or Fisher’s exact test) for categorical variables; the 
Kruskal-Wallis test was used for ordinal or continuous variables with skewed distributions.  
DIC/DIP: Negative DIC/DIP responses were coded as -2 (strongly disagree) or -1 (disagree) and 
positive responses as +1 (agree) or +2 (strongly agree).24,27 Missing responses were imputed using the 
mean of the non-missing items within the assessment domain for the individual. Mean proportion of 
missing responses was 4.5% (SD=1.4%) for the DIP (range 2.8%-7.6% for a single item) and 2.2% 
(SD=1.0%) for the DIC (range 0.9%-4.1%). 
Cronbach’s alpha was used to assess the internal consistency of the three DIC/DIP domains. For 
domains with alphas <.70, inter-item correlation matrices, item correlation with total, and changes to 
alpha by item were examined to detect problematic items; these items were excluded from subsequent 
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analyses.  
Mean DIC/DIP scores for feasibility, acceptability, and utility were compared within patient and 
clinician cohorts, cross-nationally and overall. We also compared the overall patient and clinician mean 
scores for each assessment domain; remaining items in domains with excluded items were also compared 
individually. To account for site-specific effects, clinicians seeing several patients, and the inclusion of 
new and existing patients to the clinic, we used generalized linear mixed-effects models (PROC 
GLIMMIX in SAS), with random intercepts for site and clinician and a fixed effect for new patient status. 
Tukey-Kramer post-hoc tests that adjust for multiple comparisons were used to identify significant 
patient-clinician differences.28  
Duration: Durations of the CFI and the full diagnostic interview (including the CFI) were compared 
separately cross-nationally using PROC GLIMMIX to adjust for new patient status and clinician effects. 
The proportion of total interview time devoted to the CFI was also calculated. 
Practice effect: To determine whether clinicians’ accumulated experience with the CFI affected their 
perceptions of the outcomes, we analysed changes in DIC scores over subsequent CFI interviews; we also 
analysed interview duration and the proportion of time devoted to the CFI in the full interview for each 
clinician. A mixed-effects model adjusted for clinician and site effects (but not patient newness, since 
patients were always new to study clinicians). Separate mixed-effects models and Tukey-Kramer post-hoc 
tests contrasted DIC assessment domains between and within each administration, respectively. 
Qualitative 
Qualitative analyses were conducted by a three-person multidisciplinary team (public health, 
sociology, and psychiatry) using deductive content analysis and working independently of the quantitative 
analysis team. Deductive content analysis codes qualitative data using pre-established categories based on 
theoretical frameworks.29,30 Each debriefing interview was coded for feasibility, acceptability, and utility 
according to a codebook (developed by NKA): feasibility and acceptability were defined as per Proctor et 
al20 and their definition for appropriateness was used to define utility, consistent with the terminology of 
the DSM-5 trials.25 Coder training consisted of two 1-hour sessions. Each coder labelled each interview 
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phrase with one unique code for feasibility, acceptability, or utility to minimize bias.31 Inter-rater 
reliability of 80% was achieved using a random 10% selection of transcripts. Iterative revision of the 
codebook was conducted over 5 weeks by reviewing concordance among codes and concepts, developing 
new sub-codes, memoing, specifying code definitions with parameters (appropriate and inappropriate 
use), and reviewing data examples until new information produced no change to coding categories. All 
debriefing interviews were uploaded into NVivo (QSR International 2012) and randomly assigned for 
coding. NVivo reports were generated for codes, exploring patterns, and drafting analytical memos by 
theme. Qualitative codes were counted by individual respondent and by number of mentions per text to 
analyse data by session and for the total sample. 
 
Results 
Patient characteristics 
The field trial enrolled 321 patients; three were under 16 and were excluded, leaving 318 for 
analysis, of whom 189 were new and 129 existing patients. They had a mean age of 41.4 and 10.6 years 
of education; half were female (Table 1 and Appendix 3). Most countries had an even distribution of 
employed, unemployed, and out-of-the-labour-force respondents (e.g., retired), except for the USA where 
nearly half were disabled. Marital status differed by country. Proportion of foreign-born individuals 
ranged widely, from 0% in Peru to 97% in Canada. Patients’ primary language varied by site. Significant 
cross-national differences were observed for all socio-demographic variables (gender: p<0.05; all others: 
p<0.001). Clinically, 70% of patients received one DSM-IV Axis I diagnosis, 20% received two, 7% 
three or more, and 2% none (Table 1); this proportion varied significantly across countries (p<0.001). 
Depressive disorders were diagnosed most frequently, followed by anxiety disorders. 
 
INSERT TABLE 1  
 
Clinician characteristics: 
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Seventy-five clinicians were enrolled, with an average age of 38.4; over 50% were female, except in 
the Netherlands and Peru (Table 2). Nearly 50% were psychiatrists or psychiatric trainees, 28% 
psychologists, and 15% social workers. Countries differed substantially on several indices. Kenyan 
clinicians had a mean of 3 years of practice, had seldom/never treated patients of different cultures, and 
all had <10 hours of cultural training. By contrast Dutch clinicians had 15.6 years of practice, 91% had 
daily cross-cultural contacts, and half had >50 hours of cultural training. The proportion of foreign-born 
clinicians ranged from 0% in India and Peru to 57% in Canada. All variables differed significantly across 
countries, except for age and gender.  
 
INSERT TABLE 2  
 
Self-report outcome ratings: 
Cronbach’s alphas for the DIC were high: 0.78 (feasibility), 0.80 (acceptability), and 0.89 (utility). 
DIP internal consistency was high for utility (0.82) but minimal for feasibility (0.18) and acceptability 
(0.17). Item-based analyses identified one problematic item under feasibility (“Took more time to share 
my perspective then I wanted”) and acceptability (“Were too personal”); both items were negatively 
worded. Removing these items27 increased Cronbach’s alpha for feasibility (0.45) and acceptability (0.48) 
(see Appendix 2), these domains each now containing two items. Prior research on cross-cultural 
variation with negatively-worded survey items supports this approach.32  
Patient and clinician ratings of feasibility, acceptability, and clinical utility were positive, but varied 
significantly cross-nationally (Appendix 4). Once adjusted for site effects, mean overall results for all 
three outcomes (Table 3) were positive among patients—scoring 1.26-1.33 on a scale from -2 to +2—but 
evaluations were less positive among clinicians, with scores of 0.93-0.98 on utility and acceptability and 
0.75 on feasibility. Overall feasibility was significantly lower than the other indices among clinicians, and 
significantly lower than patients’ feasibility rating. Clinicians also rated acceptability and utility lower 
than patients, but not significantly. By contrast, patient scores across assessment domains were nearly 
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identical.  
After excluding the two problematic DIP items, comparison of remaining single-item ratings of 
feasibility (easy to understand, t(10)=5.27, p<.001; improved flow, t(10)=2.32, p=.043) and acceptability 
(encourage clinician use, t(10)=2.17, p=.055; felt at ease, t(10)=21.3, p=.059) across patient and clinician 
assessments revealed the same pattern as the analysis of means. DIC single-item results (Appendix 2) 
identified clinician concerns about CFI comprehensibility and interview flow (feasibility) and about CFI 
impact on clarification of diagnosis, cultural background, severity, and patient-clinician differences 
(utility). DIP single-item results did not indicate specific concerns, although identification of barriers to 
care (utility) scored somewhat lower than other items. 
 
INSERT TABLE 3  
 
Duration: 
Average CFI duration ranged from 18.8 minutes in the Netherlands to 29.2 in Kenya (p<0.001) and 
total interview duration ranged from 37.6 minutes in Kenya to 88.2 in the Netherlands (p<0.001). 
Average overall CFI duration was 23.4 minutes, within a 54.1-minute intake. Cross-nationally, the 
proportion of the interview devoted to the CFI varied significantly (Appendix 4). 
Practice effects 
Clinician (DIC) feasibility ratings improved significantly with practice, from an average of 0.59 at 
first use to 0.96 at the sixth or subsequent administration (Table 4). Acceptability and utility scores, by 
contrast, were stable and positive over time. Feasibility differed significantly from acceptability and 
utility ratings only for the first administration. Mean CFI duration decreased significantly, by over 4 
minutes, consistent with clinician’s reports of increasing confidence in feasibility. This effect on CFI 
duration was evident by clinicians’ second CFI administration, and remained stable at 22-23 minutes 
thereafter. Mean total diagnostic interview duration also decreased significantly but gradually, by over 12 
minutes from first to last administration. CFI proportion of the total interview time increased slightly with 
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practice. 
 
INSERT TABLE 4  
 
Qualitative interviews 
Qualitative coding of the post-CFI open-ended debriefing interviews identified a pattern similar to 
the closed-ended quantitative DIC/DIP analysis (Appendix 5). Clinicians had a more negative perception 
of CFI feasibility than patients: 107 of 318 clinician interviews included negative feasibility comments 
about the CFI as a tool, and 39 negative feasibility comments concerning prospects for clinical 
implementation, compared to only 26 and 7 negative comments, respectively, among 318 patients. By 
contrast, patients made 81 positive feasibility comments about the CFI and 14 positive feasibility 
comments about its implementation prospects, while clinicians only made 30 and 9 positive comments, 
respectively. Clinicians’ concerns focussed on feasibility; acceptability and utility elicited more positive 
views. By contrast, patients’ comments were largely positive across all assessment domains. These 
patterns were identical whether views were coded by participant or by total number of utterances.  
Clinicians were concerned about the CFI’s feasibility as a tool, faulting its organization (“jumbled”) 
and its placement early in the clinical interview. They also worried about implementation-related issues, 
such as time burden and whether the format was overly structured. Patients were more positive about 
feasibility, praising the CFI structure (“from basic questions to more complex…in the sense of how you 
feel”) and clinicians’ non-“pressured” administration. However, some patients found “all the details” 
confusing; they also worried the CFI might be too time-consuming for busy clinicians.  
Regarding acceptability, clinicians praised the CFI’s ability to generate empathy but found some 
questions difficult to administer (e.g., on the clinician-patient relationship). Patients liked the flow and 
person-centeredness of the CFI questions (“I felt like I was talking to someone I knew”), though some 
became upset by the life content elicited.  
The views on CFI utility were the most positive. Generally, both groups of participants found the 
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CFI useful with respect to diagnosis, treatment planning, and understanding the patient’s situation, 
including the role of culture in mental illness (e.g., “will help me get better treatment;” “will help me 
understand the patient’s problem extensively on the basis of cultural, religious things”). 
 
Discussion 
The DSM-5 Cultural Formulation Interview field trial was the first international study to examine 
clinician and patient perceptions of the feasibility, acceptability, and clinical utility of a cultural 
assessment interview designed for use in routine clinical practice in diverse cross-national settings. The 
international trial recruited 321 patients and 75 clinicians over 11 sites in 6 countries. Mixed-methods 
analyses showed that both patients and clinicians found the CFI to be feasible, acceptable, and clinically 
useful, and these findings supported its inclusion in DSM-5. The diversity of the samples and sites – and 
the fact that both closed-ended and open-ended assessments yielded similar results when analysed blind to 
one another – enhance the clarity, robustness, and generalizability of our findings.  
The strategy for our quantitative analysis was developed at one of the study sites in India and used 
here with minor modifications. 27 Site-specific analyses of the field trial data have also found positive 
perceptions of implementation-related outcomes.19,24,27 In the full sample, patients assessed the CFI more 
positively than clinicians, and the difference was significant for feasibility. Clinicians were more 
concerned about feasibility than about acceptability or utility. The qualitative data, based on post-CFI 
open-ended interviews, likewise showed greater clinician concern about feasibility, compared to patient 
views and other clinician-rated outcomes.  
To be successfully implemented, a new assessment should address the concerns of all stakeholders;33 
our design enabled us to examine views of both clinicians and patients. Differing views of feasibility 
among stakeholders probably reflect practical concerns and limited time of busy clinicians,34 relevant for 
effective allocation of health system resources that must balance clinical values and practical 
constraints.35 Although stakeholders’ perceived acceptability and utility of an assessment or intervention 
may conceivably differ,20,36 we found no significant differences in our field trial.  
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Our mixed-methods design identified barriers to implementation of the CFI field trial version. DIC 
single-item analysis and qualitative data largely converged. They also confirm a previously-published 
subanalysis of New York-site qualitative data, which had identified lack of differentiation of the CFI from 
routine clinical assessments, question clarity and ordering, and the time required for the interview as main 
concerns.19 The consistency of these concerns in our cross-national analysis is striking, given the cultural 
and clinical diversity among study participants.  
Many of these issues were addressed in the revised version of the CFI published in DSM-5. Based on 
the field trial results, the revision clarified confusing wording, improved the flow of questions, and 
distinguished the intent of the CFI from other aspects of clinical management. Four questions were 
condensed into two, and one question on cultural identity and three on the views of the patient’s social 
network were added. Future research should examine the impact of implementing the CFI on clinical 
practice and outcomes, and in cultural competence training.  
The practice effect identified from self-report and interview-duration data has important implications 
for questions about feasibility. Findings suggest that two hours of training followed by experience 
administering a few interviews may be sufficient to address clinicians’ concerns about feasible use of the 
instrument, even in a diverse sample of provider disciplines and of cultural competence experience across 
sites.25 Consideration of the practice effect may facilitate uptake of the CFI, mindful that implementing 
any new tool may initially evoke resistance,27 which may lessen over time if its relative advantage 
becomes clear in routine practice.37 Indeed, by the second CFI administration, clinician feasibility scores 
increased substantially and no longer differed significantly from clinician acceptability and utility scores. 
Duration of the CFI interview, an objective indicator of feasibility, showed a similar practice effect, 
decreasing by 4 minutes by the second administration and remaining stable thereafter.  
Duration of the full diagnostic interview also decreased significantly albeit more gradually. By the 
last administration, the duration of the full intake assessment, including 22 minutes for the CFI, was 50 
minutes. This is comparable to the time required for an initial assessment in many mental health settings. 
In the USA, for example, average duration of community-based psychiatric visits (initial and follow-up 
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combined) was 32–38 minutes in 1989–2006;38-40 intakes are often 45-50 minutes. Our study found 
substantial international variation in intake duration. Some of this variation may derive not only from 
resource constraints—few clinicians for many patients—but also from clinic characteristics. The sites 
with the longest intakes (Canada and the Netherlands) included specialized programs for immigrants and 
refugees, whereas most other sites operated in general community clinics. Sites also differed significantly 
in the proportion of total interview time devoted to the CFI, yet all were able to integrate the CFI into 
routine intake procedures. The proportion of the interview devoted to the CFI increased slightly with 
experience, suggesting clinicians continued to find it useful and that the information it yielded was 
relevant to other aspects of the diagnostic interview, inasmuch as less time was required for the overall 
interview as a practice effect.   
This study has several limitations. Participating clinics were recruited purposively and may pay 
higher-than-average attention to cultural issues; clinicians who were most interested may have done more 
interviews, potentially confounding the positive practice effect. However, clinicians’ interest did not 
prevent them from stating their concerns candidly in the qualitative interviews. Second, we developed our 
own self-report measures of service outcomes because at the time of the field trial there were no 
psychometrically-validated quantitative measures of implementation-related outcomes.41 The DIP 
feasibility and acceptability domains of assessment had psychometric limitations. One-time use of these 
assessments is consistent with the DSM-5 field trial goal of testing proposed diagnostic criteria (or tools 
such as the CFI) for inclusion or revision in the final manual.22 The congruence of the qualitative and 
quantitative results as a benefit of the mixed-methods design supports the robustness of the DIP data. 
Third, the study interview consisted of the CFI session followed by the routine diagnostic assessment. All 
clinicians were asked to inform patients when they transitioned from the CFI to the routine assessment. It 
is possible that some patients did not distinguish the CFI component of their evaluation from the routine 
diagnostic component when responding to questions in their debriefing interviews. 
Despite these limitations, the DSM-5 international field trial results support the feasibility, 
acceptability, and clinical utility of the Cultural Formulation Interview. The positive valuation by patients 
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and clinicians suggests that it is worth investing about 20 minutes of an initial evaluation on a cultural 
assessment that holds promise for enhancing clinical communication, diagnostic accuracy, effective 
treatment planning, patient satisfaction, engagement, and clinical response.19,21 The promise of such 
benefits argues for further study of CFI implementation effects on clinical and service outcomes (e.g., 
cost and sustainability).20 As a practical matter, the field trial suggests an attractive learning curve, with 
clear benefits after two hours of training and a single interview. A 2014 Lancet Commission on culture 
and health advocated use of the CFI in all medical subspecialties, not just psychiatry,42 highlighting its 
broad relevance. Although further studies of implementation outcomes are needed, our findings indicate 
good prospects for meeting these acknowledged needs.  
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Table 1. Patient sample characteristics (N=318) 
 
Patients Canada 
(n=33) 
India  
(n=101) 
Kenya 
(n=29) 
Netherlands 
 (n=30) 
Peru  
(n=34) 
USA  
(n=91) 
Total  
(n=318) 
Test Statistic 
(df) 
p-value 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
 
  
Age 51.12 (15.85) 35.42 (12.85)b 31.97 (10.77) 41.87 (15.33) 36.50 (10.47)b 49.25 (13.62)b 41.44 (14.95) F(5,306) = 17.56 <0.001*** 
Years of 
Education 
7.53 (4.94)a 11.37 (4.21) 9.83 (3.37) 12.03 (4.97) 12.56 (2.83) 9.94 (4.78)c 10.64 (4.52) F(5,101) = 6.92 <0.001*** 
 N % N % N % N % N % N % N %   
Female 21 63.64 42 41.58 14 48.28 9 30.00 20 58.82 50 54.95 156 49.06 Fisher’s Exact 
Test 
0.011* 
Foreign-born 32 96.97 1 0.99 1 3.45 17 56.67 0 0 61 67.03 112 35.22 χ2(5) = 187.75 <0.001*** 
New to CFI 
clinic 
33 100 101 100 0 0 20 66.67 34 100 1 1.10 189 59.43 χ2(5) = 286.25 <0.001*** 
Number of Axis I diagnoses 
0 2 6.06 3 2.97 0 0 1 3.33 0 0 1 1.10 7 2.20 χ2(5) = 55.97 <0.001*** 
1 25 75.76 91 90.10 26 89.66 12 40.00 20 58.82 49 53.85 233 70.13   
2 5 15.15 6 5.94 3 10.34 9 30.00 10 29.41 32 35.16 65 20.44   
3 or more 1 3.03 1 0.99 0 0 8 26.67 4 11.76 9 9.89 23 7.23   
a. Data unavailable for 1 participant; b. for 2 participants; c. for 10 participants 
*p<0.05; **p<0.01, ***p<0.001.    
Table 2. Clinician sample characteristics (N=75) 
 
Clinicians Canada  
(n=7) 
India  
(n=21) 
Kenya  
(n=5) 
Netherlands  
(n=11) 
Peru  
(n=5) 
USA 
(n=26) 
Total  
(N=75) 
Test Statistic 
(df) 
p-value 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)   
Age 37.57 (7.76) 34.67 (7.48) 33.40 (4.39) 43.64 (11.46) 39.60 (8.26) 40.08 (10.26)a 38.35 (9.12) χ2(5) = 10.39 0.065 
Years providing 
mental health care 
10.14 (5.24) 7.48 (7.09) 3.00 (1.22) 15.55 (12.64) 6.60 (4.34) 10.16 (8.61)a 9.47 (8.58) χ2(5) = 13.12 0.022* 
 N % N % N % N % N % N % N %   
Female 6 85.71 12 57.14 3 60.00 5 45.45 1 20.00 14 53.85 41 54.67 Fisher’s Exact Test 0.377 
Professional Discipline 
Psychiatrist/ 
Psychiatry Trainee  
2 28.57 15 71.43 5 100 2 18.18 5 100 8 30.77 37 49.33 Fisher’s Exact Test <0.001*** 
Psychologist 1 14.29 2 9.52 0 0 6 54.55 0 0 12 46.15 21 28.00   
Social Worker 1 14.29 4 19.05 0 0 3 27.27 0 0 3 11.54 11 14.67   
Other Mental 
Health Clinician1 
3 42.86 0 0 0 0 0 0 0 0 3 11.54 6 8.00   
Foreign-born 4 57.14 0 0 1 20.00 2 18.18 0 0 11 42.31 18 24.00 Fisher’s Exact Test <0.001*** 
Frequency of contact with 
   patients of different cultures 
Daily 4 57.14 12 57.14 0 0 10 90.91 1 20.00 19 73.08 46 61.33 Fisher’s Exact Test <0.001*** 
Weekly or Monthly 0 0 9 42.86 0 0 1 9.09 4 80.00 4 15.38 18 24.00   
Seldom or Never 3 42.86 0 0 5 100 0 0 0 0 3 11.54 11 14.67   
Hours of cultural training 
< 10 hours 2 28.57 6 28.57 5 100 3 50.00b 0 0 3 11.54 19 27.14 χ2(5) = 14.05 0.015* 
10 – 50 hours 1 14.29 11 52.38 0 0 0 0b 3 60.00 11 42.31 26 37.14   
>50 hours 4 57.14 4 19.05 0 0 3 50.00b 2 40.00 12 46.15 25 34.71   
a. Data unavailable for 1 participant; b. for 5 participants. 
1. Other clinicians: Licensed Marriage and Family Therapist (n=1 person), Social Work intern (n=1), Rehabilitation Counselor (n=1), Psychology trainee (n=2), 
Unspecified clinician (n=1). 
*p<0.05; **p<0.01, ***p<0.001.  
Table 3. Comparing feasibility, acceptability, and clinical utility of the CFI from Likert-scale 
debriefing questionnaires, by clinicians and patients (N=315) 
 
 Domain 
 
 
 Feasibility    M (SD) 
Acceptability 
    M (SD) 
Clinical Utility 
     M (SD) Test Statistic (df) p-value 
Patients 1.33 (0.57)  1.27 (0.71)   1.26 (0.53)  F(2,833) = 1.41   0.246 
Clinicians 0.75 (0.90) a,b  0.98 (0.75) a   0.93 (0.70) b  F(2,864) = 13.37 <0.001*** 
Test Statistic (df) t(10) = 3.53  t(10) = 1.65   t(10) = 2.14   
p-value      0.005**       0.131        0.058   
Mixed-effect models compared domain score differences within and between groups, controlling for clinicians 
seeing multiple patients, multiple clinicians within a site, and whether the patient seen was new to the clinic. 
Data unavailable for the following parameters: Patient acceptability (n=16), Patient feasibility (n=13), Patient utility 
(n=5), and Clinician acceptability (n=3). 
a,b. Values with paired superscripts in the same row differ significantly (p< 0.05) after adjusting for multiple 
comparisons, Tukey-Kramer test. 
*p<0.05; **p<0.01, ***p<0.001. 
  
Table 4. Practice effects on feasibility, acceptability, clinical utility, interview duration, and proportion of total interview devoted to the 
CFI, in successive clinician interviews using the CFI (N=316) 
 
Number of CFI 
administrations  
First 
(n=74) 
Second 
(n=68) 
Third 
(n=67) 
Fourth 
(n=42) 
Fifth 
(n=26) 
Sixth1 
 (n=39) 
Beta 
(95% CI) 
p-value 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
 
  
Feasibility 0.59 (1.02) †‡ 0.81 (0.95) 0.72 (0.92) 0.84 (0.66) 0.72 (0.94) 0.96 (0.67)a 0.053 
(0.003, 0.103) 
0.039* 
 
Acceptability 1.01 (0.72) † 0.98 (0.78) 0.97 (0.76)a 0.98 (0.79)b 0.87 (0.74) 0.98 (0.70)a -0.011 
(-0.051, 0.029) 
0.591 
Clinical Utility 0.96 (0.65) ‡ 0.92 (0.82) 0.84 (0.66) 0.91 (0.74) 0.98 (0.66) 1.06 (0.66)a -0.013 
(-0.046, 0.021) 
0.458 
         
Duration of CFI in minutes 26.44 (10.40)c 22.23 (9.64)e 22.87 (9.38)b 22.16 (8.77)a 23.42 (9.57)a 22.28 (8.39) -1.017 
(-1.616, -0.418) 
0.001** 
Duration of full diagnostic 
interview in minutes 
62.70 (27.41)d 54.26 (25.95)f 53.67 (23.58)g 48.21 (21.49)g 47.92 (22.55) 50.43 (28.61)b -1.609 
(-2.708, -0.510) 
 
0.004** 
CFI proportion of total 
diagnostic interview 
47.49% (21.95)d 47.62% (22.47)f 48.91% (22.72)g 51.67% (21.62)g 54.07% (17.69)a 51.94% (18.61)b 0.046% 
(-0.753, 0.845)  
   0.910 
 
Mixed-effect model comparisons control for clinicians seeing multiple patients and multiple clinicians within a site. 
1. Combines the sixth administration or greater into one group. 6th=18 individuals, 7th=9, 8th=5, 9th=4, 10th=3. 
a. Data unavailable for 1 participant; b. for 2; c. for 6; d. for 10; e. for 4; f. for 5; g. for 3. 
†‡. Values with paired superscripts in the first-administration column differ significantly (p< 0.05) after adjusting for multiple comparisons, Tukey-Kramer test. No 
other values differed significantly within administrations. 
*p<0.05; **p<0.01, ***p<0.001. 
Appendix 1 
 
The Field Trial Version of the Core Cultural Formulation Interview 
 
1. What problems or concerns bring you to the clinic? 
2. What troubles you most about your problem? 
3. People often understand their problems in their own way, which may be similar or different from how 
doctors explain the problem. How would you describe your problem to someone else? 
3a. Sometimes people use particular words or phrases to talk about their problems. Is there a 
specific term or expression that describes your problem? 
3b. What is it? 
4. Why do you think this is happening to you? What do you think are the particular causes of your 
problem? 
5. What, if anything, makes your problem worse, or makes it harder to cope with?  
5a. What have your family, friends, and other people in your life done that may have made your 
problem worse? 
6. What, if anything, makes your problem better, or helps you cope with it more easily? 
6a. What have your family, friends, and other people in your life done that may have made your 
problem better? 
7. Is there anything about your background, for example your culture, race, ethnicity, religion or 
geographical origin that is causing problems for you in your current life situation? In what way? 
8. On the other hand, is there anything about your background that helps you to cope with your current 
life situation? In what way? 
9. Sometimes people consider various ways of making themselves feel better. What have you done on 
your own to cope with your problem? 
10. Often, people also look for help from other individuals, groups, or institutions to help them feel 
better. In the past, what kind of treatment or help from other sources have you sought for your 
problem? 
10a. What type of help or treatment was most useful? Why?/How? 
10b. What type of help or treatment was not useful? Why?/How? 
11. Has anything prevented you from getting the help you need—for example, cost or lack of insurance 
coverage, getting time off work or family responsibilities, concern about stigma or discrimination, or 
lack of services that understand your language or culture? What got in the way? 
12. Now let’s talk about the help you would be getting here. Is there anything about my own background 
that might make it difficult for me to understand or help you with your problem? 12a. In what 
way?/Why not? 
13. How can I and others at our clinic be most helpful for you? 
14. What kind of help would you like from us now, as specialists in mental health? 
1 
 
Appendix 2 
 
Reliability of the Debriefing Instrument for Patients and the Debriefing Instrument for Clinicians 
 
 The Debriefing Instrument for Patients (DIP) and the Debriefing Instrument for Clinicians (DIC) are each 
composed of three domains that assess respondents’ perceptions of the feasibility, acceptability, and clinical 
utility of the Cultural Formulation Interview. We estimated the reliability (both raw and standardized coefficient 
α) of each domain prior to calculating mean DIP and DIC scores. While the DIC items appeared reasonably 
reliable as written, the DIP items showed greater variation; psychometric evaluation led to the exclusion of two 
items, one in the feasibility domain and one in the acceptability domain. This document describes the procedures 
we followed to reach this conclusion. The psychometric analyses of the DIP clinical utility domain and all three 
DIC domains are not presented in this document, since no differences between raw and standardized α’s were 
observed; all of the domains had adequate reliability, item correlations with total, inter-item correlations, and 
changes to α by item; and no items in these domains were changed or removed. The final DIP and DIC item-based 
results and α coefficients are presented in Table 1 below.  
 
Table 1. Final domain items, means, and reliability estimates for Debriefing Instrument – Patients and Clinicians1 
Patient interviews    Clinician interviews   
Domains and items Mean SD  Domains and items Mean SD 
Feasibility (n = 302)    Feasibility (n = 312)   
α =0.45  (Raw = 0.45)    α = 0.78  (Raw = 0.77)   
09. Were easy to 
understand 
1.37 0.72  12. Were easy to administer 0.97 0.97 
11. Improved the flow of the 
interview 
1.30 0.71  13. Were easily understood by the 
patient 
0.56 1.14 
    14. Contributed positively to the flow 
of my clinical interview 
0.77 1.11 
Acceptability (n = 299)    Acceptability (n=297)   
α = 0.48 (Raw = 0.49)    α = 0.80  (Raw=0.79)   
13. Should be asked by every 
clinician. 
1.14 0.99  15. Helped make the patient feel more 
at ease during the interview 
0.91 1.01 
14. Helped me feel more at ease 
with the interview 
1.40 0.75  16. Can be incorporated by mental 
health clinicians into routine clinical 
interviews 
1.06 0.87 
    17. Facilitated a good assessment of 
cultural factors relevant to clinical 
care 
0.95 1.01 
    18. I would recommend for use by 
other mental health clinicians 
1.08 0.84 
Clinical Utility (n = 275)    Clinical Utility (n = 290)   
α = 0.82  (Raw = 0.82)    α = 0.89  (Raw=0.89)   
01. Helped me explain my main 
concerns 
1.48 0.56  01. Helped me understand the 
patient’s cultural background 
0.74 1.11 
02. Helped me communicate 
important aspects of my 
background, such as religious 
faith and/or culture 
1.20 0.83  02. Clarified the patient’s ideas about 
the cause of the problem 
0.98 1.01 
03. Helped me understand how 
my background and current 
situation affect my problem 
1.20 0.85  03. Clarified my understanding of the 
patient’s symptoms and problems 
0.95 1.03 
04. Helped me explain what kinds 
of help I would like 
1.36 0.69  04. Gave me confidence in the 
diagnosis 
0.58 1.24 
2 
 
05. Gave me confidence that the 
clinician understood my situation 
1.50 0.68  05. Facilitated treatment planning 0.98 1.06 
06. Helped me identify things that 
could get in the way of my 
treatment 
1.05 0.97  06. Helped me identify issues that 
could interfere with treatment 
adherence 
1.11 0.95 
07. Encouraged me to share 
important information that might 
not have been mentioned 
otherwise 
1.21 0.93  07. Helped me identify additional 
aspects or dimensions of the patient’s 
clinical problems 
1.04 1.01 
08. Were useful overall 1.44 0.62  08. Helped me assess the severity of 
the patient’s clinical problems 
0.77 1.11 
    09. Facilitated my rapport with the 
patient 
1.16 1.02 
    10. Clarified how my perspective on 
the patient’s presentation was similar 
or different to the patient’s 
0.79 1.10 
    11. Were useful overall 1.12 0.75 
1. Standardized α’s are reported in bold, with raw α’s in parentheses 
 
 All reliability calculations were conducted with SAS Version 9.4 (Cary, NC) using the CORR procedure 
with the ALPHA and NOMISS options. Only patients and clinicians who answered every item within a domain 
were included for the reliability analyses. Sample sizes increased between calculations done with the full DIP 
domains and the reduced DIP domains because the former excluded patients who did not provide answers for 
items that were ultimately removed (DIP item 10 and 12). Alpha estimates and item means were recalculated after 
these items were identified and removed. Subsequent domain scores are based on these reduced scales.  
 
DIP DOMAINS ON FEASIBILITY AND ACCEPTABILITY 
 The Feasibility and Acceptability domain each included one negatively-worded item intended to be 
scored in reverse (items 10 and 12; Table 2); these two domains had the lowest standardized α’s (0.18 and 0.17, 
respectively) after applying the reverse-scoring scheme. There was also a large difference between the raw and 
standardized α’s of these two domains (0.07 and 0.18; 0.07 and 0.17, respectively), suggesting that the variance of 
at least one item within each domain was appreciably different from that of the other items (DeVellis, 2012). The 
Clinical Utility domain produced acceptable α values with no difference between the raw and standardized 
versions (both α’s=0.82) and is included fully in Table 1. Such low α’s for the Feasibility and Acceptability 
domains warranted a search for problematic items.  
 
Table 2. Debriefing Instrument for Patients (DIP), original domain composition using all items: reliability estimates and item 
means. 
Patient interviews    
Domains and items Domain α Mean SD 
Feasibility (n=298) Raw: 0.07 Standardized: 0.18   
09. Were easy to understand  1.36 0.72 
10. Took more time to share my perspective than I wanted. r.  -0.20 1.33 
11. Improved the flow of the interview  1.30 0.72 
Acceptability (n=295) Raw: 0.07 Standardized: 0.17   
12. Were too personal. r.  0.28 1.23 
13. Should be asked by every clinician.  1.14 1.00 
14. Helped me feel more at ease with the interview  1.41 0.74 
r. Reverse-scored 
 
Feasibility: Table 3A lists the correlation of each item of the Feasibility domain with the total correlation of the 
3 
 
remaining items. DIP 10 clearly stands out as unusual, producing a weak negative correlation with the other items 
despite reverse-coding the negatively-worded item.  
 
 
Table 3. DIP individual item correlation with total, by domain 
A. 
DIP Feasibility Correlation with Total 
 Raw Standardized 
DIP 09 0.197065 0.262147 
DIP 10 r. -0.053345 -0.053513 
DIP 11 0.013819 0.102627 
r. Reverse-scored 
 
B. 
DIP Acceptability Correlation with Total 
 Raw Standardized 
DIP 12 r. -0.088108 -0.075912 
DIP 13 0.044750 0.130489 
DIP 14 0.215033 0.246186 
r. Reverse-scored 
 
 
Table 4A examines the inter-item correlations more closely, displaying the correlation matrix among the 
three items in the domain. Item 09 appears to be moderately correlated with item 11, but weakly correlated with 
item 10. Item 11 also appears to be poorly correlated with item 10, as well as negatively correlated. 
 
Table 4. DIP inter-item correlation matrix, by domain 
A. 
DIP Feasibility DIP 09 DIP 10 r. DIP 11 
DIP 09 1.000 0.05439 0.28935 
DIP 10 r.  1.000 -0.1403 
DIP 11   1.000 
r. Reverse-scored 
B. 
DIP Acceptability DIP 12 r. DIP 13 DIP 14 
DIP 12 r. 1.000 -0.13121 -0.00803 
DIP 13  1.000 0.31649 
DIP 14   1.000 
 
 
Table 5 presents changes to α values if an item were dropped. The α of the Feasibility domain (Table 5A) 
increases substantially when item 10 is removed (raw and standardized α=0.44), providing further evidence that 
4 
 
item 10 may not fit with the other two items. If any other item were to be removed, the α value decreases further 
(dropping item 11) or results in a negative value (item 09). In the latter case, the hypothetical domain composed 
of items 10 and 11 produces a negative α, suggesting that the items may not be measuring the same construct. The 
fact that the raw and standardized α’s are essentially identical after dropping item 10 also suggests that the 
variance between item 09 and 11 is similar.  
 
Table 5. Original DIP coefficient α after deleted item 
A. 
DIP Feasibility   
Deleted Item Raw α Standardized α 
DIP 09 -0.27 -0.33 
DIP 10 r. 0.45 0.45 
DIP 11 0.09 0.10 
 
B. 
DIP Acceptability   
Deleted Item Raw α Standardized α 
DIP 12 r. 0.46 0.48 
DIP 13 0.01 0.02 
DIP 14 -0.29 -0.30 
 
For these reasons we excluded item 10 from DIP-Feasibility scoring. Including the patients who were 
excluded from the full DIP-Feasibility reliability calculation due to missing item 10, the final standardized α 
estimate was 0.45. 
 
Acceptability: In the Acceptability domain the reverse-scored item was also problematic. Item 12 correlated 
poorly and negatively with the total remaining items (Tables 3B and 4B). Alpha also improved substantially once 
the item was removed (Table 5B). Removing any other item resulted in an α nearly at 0 (dropping Item 13) or a 
negative α (dropping Item 14). As in the Feasibility domain, it appears that the reverse-scored item may not be 
measuring the intended construct. Dropping this item also produced very similar raw and standardized α 
estimates.  
Therefore, we excluded item 12 from DIP-Acceptability scoring. Including the patients who were 
excluded from the original reliability calculation for missing item 12, the final standardized α for DIP-
Acceptability was 0.48. 
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Appendix 3. Additional patient sample characteristics of the CFI international field trial 
 
Patients Canada 
(n=33) 
India 
(n=101) 
Kenya  
(n=29) 
Netherlands 
(n=30) 
Peru  
(n=30) 
USA  
(n=91) 
Total  
(n=318) 
Test 
Statistic 
p-value 
          
 N % N % N % N % N % N % N %   
Employment Status               Fisher’s  <0.001*** 
Employed (full- or 
part-time for pay) 
12 36.36 45 44.55 7 24.14 7 23.33 12 35.29 16  17.58 99 31.13 Exact 
Test 
 
Unemployed 11 33.33 18 17.82 13 44.83 13 43.33 11 32.35 15 16.48 81 25.47   
Out of labour force 10 30.30 38 37.62 9 31.03 9 30.00 11 32.35 57 62.64 134 42.14   
Other 0 0 0 0 0 0 1 3.33 0 0 3 3.30 4 1.26   
Marital Status               Fisher’s  <0.001*** 
Never married 2 6.06 34 34.00a 11 37.93 15 50.00 22 64.71 39 43.33a 123 38.92 Exact  
Married/living with 
spouse 26 78.79 60 60.00
a 9 31.03 13 43.33 9 26.47 17 18.89a 134 42.41 Test  
Separated/Divorced 3 9.09 3 3.00a 7 24.14 2 6.67 3 8.82 27 30.00a 45 14.24   
Widowed 2 6.06 1 1.00a 2 6.90 0 0 0 0 5 5.56a 10 3.16   
Other 0 0 2 2.00a 0 0 0 0 0 0 2 2.22a 4 1.27   
Primary Language                 
African languagesb 1 3.03 0 0 29 100 5 16.67 0 0 0 0 35 11.01   
Chinese languagesc 0 0 0 0 0 0 0 0 0 0 10 10.99 10 3.14   
Dutch 0 0 0 0 0 0 14 46.67 0 0 0 0 14 4.40   
English 1 3.03 3 2.97 0 0 2 6.67 0 0 28 30.77 34 10.69   
Indian languagesd 0 0 98 97.03 0 0 0 0 0 0 0 0 98 30.82   
Portuguese 30 90.91 0 0 0 0 0 0 0 0 0 0 30 9.43   
Spanish 0 0 0 0 0 0 0 0 34 100 50 54.72 84 26.42   
Othere 1 3.03 0 0 0 0 9 30.00 0 0 3 3.30 14 4.09   
Regional Race/Ethnicity-
Related Characteristicsf 
 
                
Foreign birth  32 96.97     17 56.67         
State of birth                 
Andhra Pradesh   1 0.99             
Assam   1 0.99             
Bihar   11 10.89             
Gujarat   2 1.98             
Haryana   3 2.97             
Himachal Pradesh   1 0.99             
Madhya Pradesh   3 2.97             
Maharashtra   32 31.68             
National Capital/ 
Territory of Delhi 
  29 28.71             
Not born in India   1 0.99             
Punjab   1 0.99             
Rajasthan   5 4.95             
Tamil Nadu   1 0.99             
Uttar Pradesh   8 7.92             
Uttarakhand   2 1.98             
Tribe                 
Arab     2 6.90           
Kalenjin     1 3.45           
Kamba     5 17.24           
Kikuyu     13 44.83           
Kisii     1 3.45           
Luhya     3 10.34           
Luo     1 3.45           
Somali     2 6.90           
Taita     1 3.45           
Race                 
Mixed, primarily 
indigenous 
        14 41.18       
Mixed, primarily black         2 5.88       
Mixed, primarily white         16 47.06       
Mixed, primarily 
Asian 
        1 2.94       
White non-Hispanic         1 2.94       
Race/Ethnicity                 
Hispanic           54 60.00a     
Non-Hispanic white           13 14.44a     
Non-Hispanic black           5 5.56a     
Non-Hispanic 
American Indian 
          1 1.11a     
Non-Hispanic East 
Asian 
          14 15.56a     
Non-Hispanic South 
Asian 
          2 2.20a     
Mixed/Other           1 1.11a     
Number of Patients with at Least One Diagnosis in Disorder Clusterg 
Anxiety Disorders 6 18.18 21 20.79 0 0 17 56.67 11 32.35 28 30.77 83 26.10   
Bipolar Disorders 1 3.03 8 7.92 7 24.14 0 0 2 5.88 14 15.38 32 10.06   
Depressive Disorders 23 69.70 33 32.67 3 10.34 22 73.33 19 55.88 46 50.55 146 45.91   
Psychotic Disorders 1 3.03 11 10.89 15 51.72 3 10.00 2 5.88 25 27.47 57 17.92   
Substance Disorders 3 9.09 9 8.91 4 13.79 2 6.67 4 11.76 14 15.38 36 11.32   
Other Disorders 3 9.09 20 19.80 3 10.34 6 20.00 9 26.47 10 10.99 51 16.04 
 
  
a. Data unavailable for 1 participant. 
b. Fular, Kirundi, Kiswahili, Moroccan, Moroccan Arabic, Rwandese, and Wolof 
c. Cantonese and Mandarin 
d. Gujarati, Hindi, Marathi, Punjabi, Tamil, Telgu, and Urdu 
e. Arabic, Armenian, Bosnian, Dari, French, Hmong, Indonesian, Ingushetian, Kurdish, and Turkish 
f. As there is no standard for reporting race and ethnicity in international trials, we instead report salient demographic factors as identified by local sites and 
recognized by governments. Therefore, not all factors will be relevant to every country. 
g. Diagnoses made after conducting CFI and a diagnostic interview. Patients can have multiple diagnoses so percentages will sum to over 100%. 
 
*p<0.05; **p<0.01, ***p<0.001. 
Appendix 4. Cross-national comparison of feasibility, acceptability, and clinical utility of the CFI 
 
Mixed-effect model comparisons control for clinicians seeing multiple patients and whether the patient was new to the clinic.  No adjustment for site was included given 
collinearity between site and country. 
Exact N’s vary for each row, due to missing data.  Data available upon request. 
 
*p<0.05; **p<0.01, ***p<0.001 
a,b,c,d,e,f,g,h. Values with paired superscripts in the same row differ significantly (p< 0.05) after adjusting for multiple comparisons, Tukey-Kramer test. 
 
 Canada 
(n=33) 
India 
(n=101) 
Kenya 
(n=30) 
Netherlands 
(n=30) 
Peru 
(34) 
USA 
(n=91) 
Overall 
(n=315) 
Statistic 
F(5) 
p-value 
 
Patients 
M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) M (SD)   
Feasibility 1.50 (0.51) 1.32 (0.47)a 1.75 (0.42)a,b,c,d 1.02 (0.66)c,e 1.21 (0.70)d 1.30 (0.58)b,e 1.33 (0.57) 4.32 0.001** 
Acceptability 1.23 (0.77)a 1.21 (0.67)b 2.00 (0)a,b,c,d,e 0.76 (0.83)c,f 1.23 (0.67)d 1.295 (0.63)e,f 1.27 (0.71) 9.34 <0.001*** 
Clinical Utility 1.49 (0.43) 1.17 (0.49) 1.56 (0.34)a 0.99 (0.56)a 1.29 (0.42) 1.27 (0.60) 1.26 (0.53) 2.60 0.026* 
Clinicians          
Feasibility 0.24 (0.83) 0.88 (0.91) 1.36 (0.49) 0.52 (0.94) 0.62 (0.76) 0.75 (0.92) 0.75 (0.90) 2.30 0.046* 
Acceptability 0.44 (0.85) 0.96 (0.80) 1.47 (0.50) 0.66 (0.69) 1.07 (0.52) 1.09 (0.65) 0.98 (0.75) 2.13 0.063 
Clinical Utility 0.27 (0.81)a,b,c 1.02 (0.65)a 1.45 (0.43)b 0.58 (0.59) 1.28 (0.43)c 0.90 (0.67) 0.93 (0.70) 4.26 0.001** 
Duration (min)           
CFI 26.89 (7.73) 23.05 (10.89) 29.21 (3.05)a,b 18.82 (8.78)a 19.68 (8.59)b 23.69 (9.24) 23.41 (9.57) 3.12 0.01* 
Total Interview 84.39 (26.45)a,b,c,d 43.43 (17.07)b,e 37.57 (3.80)c,f 88.18 (29.20)e,f,g,h 37.83 (13.52)d,g 54.04 (16.68)a,h 54.12 (25.61) 22.46 <0.001*** 
CFI proportion 
of total interview 
 
35.20% (15.53)a 53.79% (18.49)b 77.37% (2.86)a,c,d 23.61% (12.00)b,c,e,f 54.29% (14.55)e 47.67% (20.42)d,f 49.52% (21.41) 9.43 0.001*** 
Appendix 5. Qualitative data on reasons for feasibility, acceptability, and clinical utility, differentiated by patients and clinicians 
Code Operationalized Sub-code Magnitude 
Patients  (N=318) 
Representative Quotes 
Clinicians (N=318) 
Representative Quotes n=Total by Distinct 
Patients 
N=Total 
by Text 
Coded 
n=Total by 
Distinct 
Clinicians 
N=Total 
by Text 
Coded 
         
Feasibility: Any discussion 
of how the CFI can be used 
in service settings. 
Issues related to 
the CFI as a tool  
Positive 
response 81 110 
“I thought it was really good. You 
go from basic questions to more 
complex.  Complex in the sense of 
how you feel.” 
30 38 
“Having a set of questions clubbed 
together focuses or brings my attention 
to the cultural, background aspects of 
patients. It brings my attention back to 
these factors, which is definitely good 
for me in terms of a reminder.” 
Neutral/ 
indifferent 
response 
10 13 “I did not understand it initially but then I think I got it.”  11 14 
“I think it’s the kind of thing I would 
like everybody to be trained on. When 
they’re evaluating someone for the first 
time, they can use these questions 
towards the end of the interview to ask 
anything that was not elicited. I don’t 
think I could see it being used at the 
beginning of the interview.” 
Negative 
response 26 36 
“It was troubling because there were 
a lot of questions. I don’t 
understand. All the details confuse 
me.”  
107 274 
“Compared to other diagnostic 
interviews I’ve done, I feel things got 
jumbled.” 
Issues related to 
implementing the 
CFI within a  
clinical setting  
Positive 
response 14 17 
“The difference is the patience of 
the doctor. I didn’t notice a pressure 
in him. I didn’t feel forced.” 
9 9 “It can definitely be used at the intake process.” 
Neutral/ 
indifferent 
response 
3 3 
"It didn't affect anything. I was not 
comfortable, but there were no 
major problems." 
6 6 “The CFI is mostly relevant for non-language concordant services.”  
Negative 
response 7 9 
“I don’t know if doctors can spend 
this much time with patients.” 39 47 
“Human resources are limited and the 
extra time required for this will increase 
patient waiting time which is already 
strained.” 
 
Acceptability 
-Any discussion of how the 
CFI elicits emotions among 
patients and clinicians. 
Positive response 187 350 
“It was a good flow. It was calm, 
easy, relaxed. I wasn’t stressed. I 
wasn’t nervous. I felt like I was 
talking to someone I knew, like a 
friend or something like that.”  
39 52 “It allows me to empathize more with the patient.” 
Neutral/indifferent response 19 20 “It didn’t change my thoughts or feelings.” 4 4 
“I feel equally comfortable [addressing 
cultural aspects of patient presentations] 
as I was prior to using CFI.” 
Negative response 19 23 
“It reminded me of how sad I was 
and how much I was suffering and 
worried; it made me think about my 
future.” 
10 11 
“I was not at all comfortable. Even 
though I explained the questions to him 
[patient], he didn’t get. So I kept 
wondering what more I could do.” 
 
Clinical Utility 
-Any discussion of the 
CFI’s perceived fit, 
relevance, or compatibility 
to address a specific 
clinical problem. 
- Diagnosis 
Positive 
response 6 7 
“I think it will be better because 
they will understand what my real 
mental illness is.” 
32 39 
“It will help in certain patients who are 
a diagnostic query. For example, for this 
patient, initially it seemed like 
psychosis, but it wasn’t so upon talking 
to the patient at length.” 
Neutral/ 
Indifferent 
response 
1 1 
“I cannot say. Maybe it helps me. It 
might help the caretaker to draw 
conclusions.”  
15 15 “It doesn’t seem to modify the diagnosis.” 
Negative 
response 0 0 n/a 5 5 
“It significantly lengthens interview 
time without getting a clear diagnostic 
picture.” 
- Treatment 
Positive 
response 137 202 
“The CFI will help me get better 
treatment because it will help the 
team better assess me and my 
problem.” 
63 80 
“What brings them to the clinic is 
always very important and helps get a 
general idea, because that sets up what 
they consider the problem to be and 
how you can engage that problem with 
treatment.” 
Neutral/ 
Indifferent 
response 
15 15 “I don’t think that there will be any effects.”  8 9 
“I don’t think it will have any impact on 
treatment.” 
Negative 
response 1 1 
“The questions couldn’t help me 
improve myself.”  1 1 
“Cultural facts might not help in 
deciding the pharmacological 
management.” 
- Role of culture  
in mental illness 
Positive 
response 21 27 
“The doctors need to understand that 
patients from this country are this 
way and they are that way from this 
other country. They are all not the 
same.” 
61 83 
“This will help me understand the 
patient’s problem extensively on the 
basis of cultural/ religious things.” 
Neutral/ 
Indifferent 
response 
2 2 
“That question about our cultural 
background was not about rites, 
rituals, and religion.  It didn’t apply 
to us, so those didn’t seem so 
helpful.” 
15 15 
“I’m finding that there are some people, 
like this particular patient who I saw 
today, who jump on it and say, ‘This is 
how culture has affected me,’ and other 
people who look at me like, ‘Are you 
crazy? I don’t even know what you’re 
talking about’.” 
Negative 
response 11 11 
“I don’t think that asking people 
about their religious backgrounds is 
right.”  
23 24 
“Different cultures have different 
beliefs, and to incorporate these might 
be difficult.” 
- General information 
gathering  
(not specific  
to diagnosis 
or treatment) 
Positive 
response 154 300 
“I would say in this interview that 
today we touched on a lot of things 
that I would have taken many 
different sessions to discuss with my 
talk therapist or psychiatrist. So 
there’s a lot more personal 
106 159 
“I learned how he being able to talk 
about his symptoms opened up his 
family to talking about the symptoms.” 
information in a shorter amount of 
time.”  
Neutral/ 
Indifferent 
response 
24 26 
“It seems like kind of the same; the 
types of interviews I’ve given in the 
past are very similar.” 
10 11 
“The CFI provides some psychosocial 
information, but that is already assessed 
in a good clinical history taking.” 
Negative 
response 6 6 
“The only thing is that sometimes 
one needs to investigate a little 
about the problem, about your 
mental or emotional problem. And 
those are the things that I don't like 
to talk about very frequently. I don't 
like to talk much about the 
problem." 
17 21 
“I think they need to streamline [the 
question about] the groups that have 
been helpful or not helpful. I think 
there’s almost too much emphasis on 
outside groups as opposed to what the 
individual has experienced.” 
n/a - not applicable 
